Anti-PD-1 Antibodies and Uses Thereof
AssigneeJounce Therapeutics, Inc.
InventorsGeorge Robert Mabry, III, Stephen Sazinsky
Life of this patent
Estimating the term…
Abstract
Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
Claims67
1-50. (canceled)
A method of treating cancer in a human subject comprising administering to the subject an effective amount of an anti-PD-1 antibody, wherein the anti-PD-1 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
A method of enhancing an immune response in a human subject comprising administering to the subject an effective amount of an anti-PD-1 antibody, wherein the anti-PD-1 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
A method of increasing activation of a T cell in a human subject comprising administering to the subject an effective amount of an anti-PD-1 antibody, wherein the anti-PD-1 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
A method of reducing tumor size in a human subject with cancer comprising administering to the subject an effective amount of an anti-PD-1 antibody, wherein the anti-PD-1 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
(canceled)
64-84. (canceled)
A method of increasing the level of at least one cytokine selected from IFNγ and IL-2 in a human subject, comprising administering to the subject an anti-PD-1 antibody, wherein the anti-PD-1 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 23;
- (d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- (e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 27.
(canceled)
The method of laim 85, wherein activation of T cells is increased following administration of the anti-PD-1 antibody.
Dependencies are inferred from the claim text.